Nearly 2,000 drug manufacturing plants are overdue for FDA inspections after COVID delays, AP finds
WASHINGTON (AP) — Federal regulators responsible for the safety of the U.S. drug supply are still struggling to get back to where they were in 2019, before the COVID-19 pandemic upended factory inspections in the U.S. and across the world, The Associated Press has found. An AP analysis of Food and Drug Administration data shows … Leer más